Corporate governance

Oversight and accountability.

Effective governance, responsible oversight and transparent communication build long-term shareholder confidence. Our Board of Directors oversees NÖK's strategy, governance practices and management accountability.

Executive leadership

Philippe Deschamps

Chief Executive Officer and Chairman of the Board

Philippe Deschamps is Chief Executive Officer and Chairman of the Board of NÖK Therapeutics. He brings nearly four decades of experience in global healthcare commercialization across the pharmaceutical, medical device, diagnostics and healthcare services sectors. At NÖK, he led the company’s quotation on the OTC market and is directing its Phase II clinical program.

As CEO of ChitogenX Inc., he raised more than $7 million, secured over $5 million in research grants and launched a multi-site Phase I/II trial in the United States. As Founder, CEO and Chairman of Helius Medical Technologies, he raised $100 million in the public markets, won Canadian regulatory clearances for the PoNS™ neuromodulation device and obtained FDA Breakthrough Device designation.

As President and CEO of GSW Worldwide, he grew the Columbus, Ohio-based healthcare agency from one office to the largest independent global healthcare agency, with offices in 13 major markets around the world. He began his career at Bayer Diagnostics and Bristol-Myers Squibb. Mr. Deschamps holds a B.Sc. in Chemistry from the University of Ottawa.

Board of Directors

Philippe Deschamps, Chairman of the Board. See his biography above.

Christopher Cochran

Director

Christopher Cochran is a member of the Board of Directors of NÖK Therapeutics. He brings more than 30 years of experience in executive leadership, business operations, technology services, sales and organizational growth, together with significant public-company governance experience.

Mr. Cochran previously served as an independent director of Nasdaq-listed Coeptis Therapeutics Holdings, Inc. During his tenure, he served on the Audit Committee and chaired both the Compensation Committee and the Nominating and Corporate Governance Committee. His board responsibilities included oversight of financial reporting, enterprise risk, executive compensation, corporate governance and management accountability.

Mr. Cochran is the Founder and Chief Executive Officer of BluChip Solutions, a technology consulting and managed-services company serving clients across healthcare, pharmaceutical, financial-services and other complex industries. Earlier in his career, he held senior sales and operational leadership positions with Hewlett Packard Enterprise, Apex Systems, Mastech Digital and Velocity World Media. He also serves as Director of the Christian Cochran Legacy Fund through The Pittsburgh Foundation. Mr. Cochran earned a Bachelor of Science in Public Administration and International Law from the University of Tennessee.

Charles Friday

Director

Charles Friday is a member of the Board of Directors of NÖK Therapeutics. He is an accomplished sales executive and strategic consultant with over 33 years of experience in financial services, sales leadership and advisor development.

He spent 31 years at Invesco, becoming its longest-tenured Senior Regional Vice President and achieving a firmwide record of $7 billion in sales. With expertise in strategic planning, performance optimization and personalized coaching, he helps financial advisors and organizations accelerate growth and achieve measurable results.

Scott Welsh

Director

Scott Welsh is a member of the Board of Directors of NÖK Therapeutics. He is Vice President of Sales at Nidec Press & Automation, a global leader in metal stamping and manufacturing automation with more than 1,000 employees across Asia, the Americas and Europe.

Mr. Welsh holds a Bachelor of Science in Mechanical Engineering from Case Western Reserve University. He lives in Pittsburgh, Pennsylvania, and is the father of four grown children.

Governance documents

Governance documents will be published here as they are adopted by the company.

Governance inquiriesQuestions about corporate governance can be sent to our investor relations contact.

Investing in biotechnology companies involves substantial risks, including risks associated with research and development, regulatory approval, financing and commercialization. Investors should review the company'sSEC filings and the risk disclosures in them before making investment decisions. Nothing on this website is an offer to sell, or a solicitation of an offer to buy, any securities, or investment advice. See our legal disclosures and forward-looking statements.